A First-in-Human Study of the Fibroblast Activation Protein–Targeted, 4–1BB Agonist RO7122290 in Patients with Advanced Solid Tumors

This first-in-human study evaluated RO7122290, a bispecific fusion protein carrying a split trimeric 4-1BB ligand and a fibroblast activation protein α (FAP) binding site that costimulates T cells for improved tumor cell killing in FAP-expressing tumors.